nanogroup.euCrawled Nov 13, 2026
Patented aptamer production methods and their applications
NanoSanguis, part of NanoGroup, develops NanOX 4 Kidney, a next-generation perfusion fluid for kidneys based on synthetic carriers.
Respiratory gas transport systems: Blood substitute and NanoOX system
Radioisotopes for diagnostics and treatment
A 2024 study published in *International Journal of Molecular Sciences* describes the development and anticancer activity of Polepi, a nanoparticle-encapsulated epirubicin, tested in ovarian cancer models.
January 26 is National Transplantation Day, promoting organ donation and transplantation procedures. Experts warn of a growing transplant crisis, with increasing waitlists and deaths for organs like kidneys, hearts, and livers.
Prof. Maciej Kosieradzki discusses NanoGroup’s NanOx technology, highlighting its potential to advance organ preservation outside the body and its unexpected benefits in research.
NanoGroup will partner with Poland’s pavilion at Expo 2025 in Osaka, Japan.
A 2025 study in *International Journal of Molecular Sciences* details the biodistribution of Polepi, a polysaccharide nanoparticle encapsulating epirubicin, tested in ovarian tumor-bearing mice.
Prof. Tomasz Ciach, a NanoGroup board member, was listed among 30 notable Warsaw entrepreneurs by *marketingibiznes.pl*.
Prof. Dr. Hab. Eng. Tomasz Ciach, Chairman of NanoSanguis’s Scientific Council, specializes in nanotechnology, holds multiple patents, and has over 50 publications.
Dr. Jarosław Woliński collaborates with NanoSanguis on the NanOx project and serves on its newly formed Scientific Council. He is an expert in animal physiology and has authored numerous scientific publications.
NanoGroup integrates nanotechnology breakthroughs with unique risk-management solutions in biotechnology.
NanoGroup’s 2023–2025 strategy aims to finalize at least one partnership project by 2024, expand its portfolio to five projects, and accelerate project timelines to commercialization.
NanoGroup’s 2026–2028 development strategy targets a top-three position among Polish biotech groups by market value.
NanoGroup and Ukraine’s Ministry of Health’s Institute of Cardiology discuss applying NanOX in heart transplantation.
